Defeating Cancer Resistance

Expanding the Scope of Treatment: One Solution for Many Mutations

Current therapies for people living with cancer target a limited number of oncogenic mutations. Increasing use of liquid biopsies and next generation sequencing is revealing a large number of oncogenic alterations for which no therapies exist. Our MasterKey approach targets broad families of oncogenic mutations, with the potential to benefit large patient populations with limited treatment options. We are advancing oral therapies designed to give patients the opportunity for a longer, healthier, active life.